Etopor IV Infusion

Etopor IV Infusion 100 mg/5 ml Introduction

Etopor IV Infusion 100 mg/5 ml is used to treat certain types of cancer. It belongs to a group of medicines called plant alkaloids and used to interfere with cancer cells growth and prevent them from reproducing. Etopor IV Infusion 100 mg/5 ml is used to treat testicular cancer, lung cancer, and other types of cancer.

Uses

Etopor IV Infusion 100 mg/5 ml is used to treat certain types of cancer, such as testicular cancer, lung cancer, and other types of cancer. It is also used in combination with other cancer medications to increase their effectiveness.

Brand Name	Etopor
Type	IV Infusion
Weight	100 mg/5 ml
Generic	Etoposide
Manufacturer	Eskayef Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Etopor IV Infusion 100 mg/5 ml works by binding to DNA and preventing DNA from replicating. This prevents the cancer cell from reproducing and growing. In addition, etoposide stimulates the body's natural mechanism to activate cells that have become trapped in a dormant state during cancer cell growth.

How Long Does it Take to Work?

Etopor IV Infusion 100 mg/5 ml generally takes a few weeks to work. The length of time depends on the type of cancer being treated and the response to the treatment.

Absorption

Etopor IV Infusion 100 mg/5 ml is rapidly absorbed by the small intestine after oral administration. The maximum plasma concentration is reached in 2 to 4 hours.

Route of Elimination

Etopor IV Infusion 100 mg/5 ml is eliminated by the kidneys. Approximately 10 to 15 percent of a single dose is excreted in the urine within 24 hours. The remainder of the drug is usually metabolized and excreted in the bile and feces.

Dosage

Small cell lung cancer: The dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m²/day for 4 days to 50 mg/m²/day for 5 days. Or, as directed by the registered physicians.

In patients with impaired renal function: The initial dose modification should be considered based on measured creatinine clearance: >50 mL/min: 100% of dose; 15-50 mL/min: 75% of dose. Subsequent Etoposide dosing should be based on patient tolerance and clinical effect. Data are not available in patients with creatinine clearances <15 ml/min and further dose reduction should be considered in these patients.

Etopor IV Infusion 100 mg/5 ml is available in tablets (50 and 100 mg), as a solution (0.5, 1 and 2 mg/ml), and as powder for injection (100 mg/10 ml). The recommended dosage depends on the type of cancer and the patient's response to treatment. Most often, the recommended daily dosage of etoposide is 50 to 100 mg per square meter of body surface area (which is about 15-30mg/kg) for at least 5 days or until the blood test results show improvement.

Administration

Etopor IV Infusion 100 mg/5 ml can be administered orally, intravenously, or by intramuscular injection. The physician should determine the most appropriate route of administration according to individual patient needs.

Side Effects

Common side effects of etoposide include nausea, vomiting, low white blood cell count, hair loss, mouth sores, fatigue, and diarrhea. Serious side effects, such as severe allergic reactions, pulmonary fibrosis, and cardiomyopathy, have also been reported.

Toxicity

Etopor IV Infusion 100 mg/5 ml is considered toxic when taken in high doses. Overdose of etoposide may cause severe nausea and vomiting, low blood cell counts, low platelet counts, kidney damage, and tremors. If an overdose is suspected, seek medical attention immediately.

Precautions

Patients taking etoposide should be monitored for blood cell counts, liver function tests, and blood pressure. Patients should also be monitored for signs of an allergic reaction. Additionally, patients taking etoposide should avoid becoming pregnant or breast-feeding while undergoing treatment.

Interactions

Etopor IV Infusion 100 mg/5 ml may interact with other medications. Before taking etoposide, patients should discuss all other medications, vitamins, and supplements with their healthcare provider. Certain medications, such as live vaccines, may interact with etoposide and should not be taken at the same time.

Disease Interaction

Etopor IV Infusion 100 mg/5 ml may interact with certain medical conditions, such as liver disease, kidney disease, and immune system problems. Let your healthcare provider know if you have any of these conditions before taking etoposide.

Drug Interactions

Etopor IV Infusion 100 mg/5 ml may interact with certain medications. Inform your healthcare provider about any medications that you are taking before starting etoposide.

Food Interactions

Avoid consuming food and juices with high alkaloid content such as grapefruit, pomelo, and guava before and while taking etoposide. Also, avoid consuming alcohol while taking etoposide.

Pregnancy Use

Etopor IV Infusion 100 mg/5 ml should not be used by pregnant women as it can cause harm to the unborn baby. Also, it is not known whether this drug passes into breast milk. Therefore, nursing mothers should not use etoposide while breastfeeding.

Acute Overdose

If an accidental overdose of etoposide occurs, seek emergency medical treatment immediately. Symptoms of an overdose may include nausea, vomiting, abdominal pain, confusion, muscle twitching, and seizures.

Contraindication

Etopor IV Infusion 100 mg/5 ml is contraindicated if a patient is allergic to it, or if a patient has certain medical conditions such as liver disease, severe kidney disease, or a weakened immune system.

Use direction

Etopor IV Infusion 100 mg/5 ml should be used as directed by a healthcare professional. It is important to follow the label instructions and the doctor’s instructions on how to use this medication. The patient should avoid drinking alcohol while taking this medication.

Storage condition

Etopor IV Infusion 100 mg/5 ml should be stored at room temperature, away from moisture and heat. Patients should not use etoposide if it has expired or is damaged.